Sutro Biopharma will host a virtual R&D Day on November 12, 2025, to present its ADC innovations and pipeline.
Quiver AI Summary
Sutro Biopharma, Inc. announced it will host a virtual Research & Development Day on November 12, 2025, at 7:00 AM PT, to showcase its platform innovations and next-generation antibody drug conjugate (ADC) pipeline. The event will be accessible via a live audio webcast, with a replay available afterwards on the company’s website. Sutro is focused on developing advanced ADCs designed to improve drug exposure and reduce side effects, aiming to address treatment resistance and expand options for cancer patients. The company's innovative approach targets significant oncology markets in need of enhanced therapies. Further information can be found on their website and social media channels.
Potential Positives
- Sutro Biopharma is hosting a virtual Research & Development Day to highlight its innovative ADC platform and pipeline, showcasing transparency and engagement with investors and stakeholders.
- The company is advancing a next-generation ADC platform that aims to improve drug efficacy and reduce side effects for cancer patients, potentially positioning it as a leader in oncology therapeutics.
- Sutro's focus on dual-payload ADCs signifies a unique approach to overcoming treatment resistance, addressing a significant need in the oncology market.
- The pipeline targets large oncology markets with limited treatment options, highlighting Sutro's commitment to developing therapies that can significantly impact patient outcomes.
Potential Negatives
- None
FAQ
What is the date of Sutro Biopharma's virtual Research & Development Day?
Sutro Biopharma's virtual Research & Development Day will be held on November 12, 2025.
How can I access Sutro Biopharma's webcast?
The webcast can be accessed at https://ir.sutrobio.com/news-events/ir-calendar.
What innovations will be discussed during the event?
The event will highlight Sutro's platform innovation and next-generation antibody-drug conjugate (ADC) pipeline.
What are the benefits of Sutro's ADC platform?
Sutro's ADC platform aims to improve drug exposure, reduce side effects, and expand treatable tumor types.
How can I contact Sutro Biopharma for investor inquiries?
For investor inquiries, contact Emily White at [email protected] or call (650) 823-7681.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STRO Insider Trading Activity
$STRO insiders have traded $STRO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STRO stock by insiders over the last 6 months:
- CONNIE MATSUI purchased 50,000 shares for an estimated $39,950
- GREGORY K. CHOW (CFO) purchased 19,750 shares for an estimated $15,997
- HANS-PETER GERBER (CHIEF SCIENTIFIC OFFICER) purchased 17,000 shares for an estimated $13,606
- JANE CHUNG (Chief Executive Officer) purchased 12,500 shares for an estimated $10,011
- DAVID PAULING (Chief Admin. Ofcr. & GC) purchased 12,504 shares for an estimated $9,993
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STRO Hedge Fund Activity
We have seen 44 institutional investors add shares of $STRO stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,434,637 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,165,887
- BLACKROCK, INC. removed 4,097,776 shares (-66.0%) from their portfolio in Q2 2025, for an estimated $2,925,402
- MILLENNIUM MANAGEMENT LLC added 4,029,088 shares (+573.0%) to their portfolio in Q2 2025, for an estimated $2,876,365
- TANG CAPITAL MANAGEMENT LLC added 2,361,586 shares (+1180.8%) to their portfolio in Q2 2025, for an estimated $1,685,936
- VELAN CAPITAL INVESTMENT MANAGEMENT LP added 2,030,000 shares (+197.1%) to their portfolio in Q2 2025, for an estimated $1,449,217
- UBS GROUP AG added 1,543,313 shares (+2042.2%) to their portfolio in Q2 2025, for an estimated $1,101,771
- STATE STREET CORP removed 1,339,687 shares (-79.6%) from their portfolio in Q2 2025, for an estimated $956,402
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STRO Analyst Ratings
Wall Street analysts have issued reports on $STRO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/16/2025
- B of A Securities issued a "Underperform" rating on 05/19/2025
To track analyst ratings and price targets for $STRO, check out Quiver Quantitative's $STRO forecast page.
$STRO Price Targets
Multiple analysts have issued price targets for $STRO recently. We have seen 3 analysts offer price targets for $STRO in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $3.0 on 08/12/2025
- Edward Tenthoff from Piper Sandler set a target price of $2.0 on 06/16/2025
- Tazeen Ahmad from B of A Securities set a target price of $0.8 on 05/19/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research & Development Day, highlighting the details of its platform innovation and next-generation ADC pipeline.
The live webcast will be held on Wednesday, November 12, 2025, starting at 7:00AM PT / 10:00AM ET.
Webcast Information:
To access the live audio webcast, please go to
https://ir.sutrobio.com/news-events/ir-calendar
. An archived replay of the webcast will be available on the Company’s website following the event.
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com .
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
[email protected]
Media Contact
Amy Bonanno
Lyra Strategic Advisory
[email protected]
